

0001178913-25-0001296-K Evogene Ltd. 2025011520250115160048160049160049 0 0001178913-25-000129 6-K 1
20250115 20250115 20250115 Evogene Ltd. 0001574565 2870 000000000 L3 1231 6-K 34 001-36187 25532886 13
GAD FEINSTEIN STREET PARK REHOVOT REHOVOT L3 7638517 97289311900 13 GAD FEINSTEIN STREET PARK
REHOVOT REHOVOT L3 7638517 6-K 1 zk2532548.htm 6-K UNITED STATES Â SECURITIES AND EXCHANGE
COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the month ofÂ January 2025 Â
Commission File Number:Â 001-36187 EVOGENE LTD. Â Â (Translation of Registrantâ€™s Name into English) Â 13
Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Â Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Â Form 20-
FÂ â˜'Â Â Â Â Â Form 40-F â˜'Â CONTENTS Â Evogene Ltd., or Evogene, reports changes in the management: Â As
part of an organizational restructuring, Mr. Eyal Ronen, the Companyâ€™s Executive Vice President of Business
Development, will conclude his employment with Evogene, effective March 4, 2025. Evogene expresses its gratitude to
Mr. Ronen for his contributions during his tenure. Â Mr. Ronenâ€™s responsibilities will be integrated into the existing
management structure, ensuring continuity and further development of our strategic initiatives. The Company remains
committed to advancing its business objectives and driving growth through collaborative efforts and innovative
solutions. Â This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration
statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and
333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on
which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Â
SIGNATURE Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â EVOGENE LTD. Â Â
(Registrant) Â Â Â Â Date: January 15, 2025 By: /s/ Yaron Eldad Â Â Yaron Eldad Â Â Chief Financial Officer Â